Welcome Ministers announcement just before BIO in May of £250 million of BBSRC grants not to mention two separate investments in synthetic biology. The Wellcome Trust has been busy too – their partnership with MRC which sees them investing £8 million in a new world class Stem Cell Institute at the University of Cambridge and the launch of their £200 million fund to invest in biotechnology start-up companies in the UK and Europe. Plus their collaboration with the Engineering and Physical Sciences Research Council (EPSRC) recently which saw them launch a joint £30 million initiative to find biomedical engineering solutions to challenging healthcare problems and the EPSRC‟s own manufacturing fellowships each worth £1 million. The good news doesn‟t end there. The latest report on the global ‘Autumn...the year's biotechnology sector from Ernst & last, loveliest smile’ Young (Beyond borders: global biotechnology report 2012) noted that the sector „showed a second Having just returned from Boston in straight year of increasingly stable the fall, I‟m reminded of this quote financial performance in 2011‟, with from William Cullen Bryant, long the established biotech markets (the time Editor of the New York Evening USA, Europe, Canada and Australia) Post. registering more than 10% revenue growth „for the first time since the Since our Spring Newsletter there start of the global financial crisis.‟ have been some other things to The analysis also points out that in smile about in the UK too - some 2011 „overall funding exploded‟ as real boosts for the sector. Not least biotechs raised a „staggering $33.4 the launch of The Biomedical billion…second only to 2000, when Catalyst – which sees £180 million the genomics bubble was at its of Government funding to bridge the height.‟ „valley of death‟ for medical breakthroughs, the Science
Tom Sommer, President MassMEDIC on Recent Activities
First Sight Media
Mike Gilham, First Sight Media on Social Media - The black hole of time?
That said, this increase was driven by a handful of commercial leaders with revenues in excess of $500 million that took advantage of low interest rates to raise large sums of debt so we shouldn‟t get carried away. But good to see some major positives. Here at One Nucleus we continue to do all we can to remain true to our mission – to help maximise our members global growth and competitiveness. I have just returned from AdvaMed (see Pages 23 and 24) where I took the opportunity to catch up with a wide range of One Nucleus friends and new contacts. Continued overleaf
One Nucleus‟ plans for Genesis 2012
Welcome Of particular note were Tom Sommer, CEO of MassMedic (see our interview with him on Page 3), Susie Kitchens, the new British Consul General in Boston and Tony Newton, ex Genzyme and now with PGD out of Maryland who is currently creating BioBrits. Susie
October 2012 delighted to introduce you to our new microsite for Genesis 2012 website: www.genesisconference.com. We are collaborating extremely closely with SCRIP Intelligence for Genesis this year (see Page 28 and 29).
each and every day. I hope you enjoy reading our Autumn Newsletter. Feedback is always extremely positive and I certainly hope it gives you a great flavour of all the fantastic work being done by our members for regional and global impact and success. The Newsletter has a distribution of 8000 around the globe so is definitely the place to be name-checked! Talking of which... our very newest member is Ricky Martin, winner of this year‟s Apprentice and Managing Director of Hyper Recruitment Solutions. We has been in situ for just over 5 New Activities very much look forward to weeks and has certainly hit the In other exciting news, here‟s a supporting his endeavours and I ground running. She is busy question for you: What do Sir Bruce personally look forward to facing working on a Cambridge to Ponder of Cancer Research UK, the steely glare of Lord Sugar Cambridge initiative that I have Ruth McKernan Senior VP of Pfizer/ himself at a Q & A meeting with committed to support her on – CSO of Neusentis and Dave him in London on 23 October. forging strong (er) than ever links Tapolczy, CEO of MRC Technology between the two Cambridge all have in common? communities. More on this as plans Answer: they are all on the develop. And Tony Newton, Chief Advisory Board for our BRAND NEW Commercial Officer at Personal Cambridge based Conference which Genome Diagnostics will be taking place on 9 July 2013. (www.personalgenome.com) who Check out Page 33 for more details recognises the consummate and to see the full Advisory Board advantage to knowing the right folk list. on that side of the pond with his launch of BioBrits. The group is a This issue of the Newsletter also very informal set of British life sees us bringing you news of a CEO science and healthcare individuals BRAND NEW service we are offering One Nucleus who are based in the Mass area and members too. The One Nucleus come together for informal Dashboard aims to give all our gatherings on a regular basis. Tony members the right information, at is very keen for UK based the right time (for you) and in the companies to feel free to access right place – see Page 29 for more this set when they are in Boston to information. have a drink together and learn from those already there who have Before I sign off, a quick reminder been there and done it and who and a pointer for those of you who may open their address books to aren‟t yet One Nucleus members. A support our members when in reminder that One Nucleus remains town. He is planning these by far the largest membership gatherings monthly, with the first organisation for life science and on 25 October (Meadhall Boston, healthcare companies in Europe, 5.30pm onwards). If you are with over 470 organisations as interested in connecting with him, members and remain incredibly do click here: www.linkedin.com/in/ proud to have each one of them in antonynewton our fold. The pointer is to our online searchable member database As many of you will know, the One (the pink button on our website – Nucleus team is always looking for www.onenucleus.com) where you brighter, stronger and more can see for yourself who we have in creative ways of doing things, our One Nucleus family. This is honing our member offer all the updated daily via Venture Valuation time. With this in mind I‟m so you are sure of the right details
‘Our very newest member is Ricky Martin, winner of this year’s Apprentice and Managing Director of Hyper Recruitment Solutions’
A First for AdvaMed In what has now become a regular feature, we talk to a One Nucleus global partner organisation - MassMEDIC’s president, Tom Sommer, on hosting AdvaMed 2012 in Boston, recent activities and ties with the UK
Tom Sommer, President MassMEDIC
real feel for the area‟s research capabilities, investment commitment and the high calibre workforce not to say the sheer volume of med tech located in the state.‟ „One highlight of the conference‟, added Sommer, „was an impressive event on the Tuesday evening hosted by the British ConsulateGeneral in Boston where we heard from Lord Howe, Parliamentary UnderSecretary for Quality, Department of Health.‟
„As you can imagine we were delighted to be hosts of AdvaMed 2012 particularly as it was the first time the conference has been held outside of Washington DC. Boston being chosen is testament to the strength of the medical device community in Massachusetts and the global reputation we have developed. It gave us the opportunity to showcase what the region has to offer not just to the US but also internationally. We saw large numbers of overseas delegates with big contingents from
„We were pleased to welcome One Nucleus leadership and members to the conference as part of the UKTI‟s involvement – without our strong UK ties this would not have been so successful.‟
Going on to talk more about MassMEDIC, Sommer added, „We were founded in 1996 by a group of like-minded medical device company executives who identified the potential for an organisation solely focused on the very unique interests of the Massachusetts‟s vibrant medical technology sector. We are now the largest regional medical device association in the US, and continue to drive success and growth with the industry and our members.‟ Sommer has led the organisation since its start, overseeing day-today operations and working closely with the executive committee and Board directors in developing its policy agenda.
„Much of my time is spent as an advocate for the industry, lobbying and promoting policies that reflect the unique interests of our members. The hard work is paying „We value the relationship with One off and after several years of being Nucleus as it provides us the in defensive mode we are now opportunity to point our members seeing positive changes to public in the UK‟s direction providing them policies that had the potential to “a soft landing point”. We are impact the success and growth of happy to be able to reciprocate and the sector. During the last year, we provide support to One Nucleus have continued to play an active members wishing to crack the US role at state level on policy issues market by harnessing all the such as repealing the “gift ban” law that would have had a chilling effect on both physicians and companies.‟
‘We value the relationship with One Nucleus as it provides us the opportunity to point our members in the UK’s direction providing them a soft landing point.’ Tom Sommer, President MassMEDIC
the UK of course, but also Canada, resources available in the China, Switzerland and the rest of Massachusetts area and providing Europe. Everyone went away with a insight and links into other regions.‟
„Unfortunately despite our every effort we were unsuccessful in fully repealing the imminent introduction of a medical device excise tax, our focus is now to ensure members are briefed and prepared for compliance in readiness for January 2013 implementation.‟
Member News Another area that Tom is passionate about is the organisation‟s commitment to helping early stage companies through MedTech IGNITE, an initiative that provides free mentoring to medical device entrepreneurs at the early stages of their company's conceptualisation, formation and development. Tom is
proud that through IGNITE, MassMEDIC have helped dozens of companies progress to next stage in their development.
device companies to develop marketing strategies that not only demonstrate safety and effectiveness of their devices but also the contribution they will make And finally, asked about the to driving down the overall cost of medical technology market moving healthcare.‟ On reflection we forward, Sommer concluded, „Set agreed this was a prediction equally against the new healthcare agenda, as applicable in the UK as it is to the pressure will be on medical the US.
One Nucleus Welcomes Steve Bates as BIA’s New Chief Executive
- „Citizens Innovation Fund report which presents a plan to „crowd source‟ new forms of funding for innovative companies and will benefit the biotech sector hugely. Steve added „Having worked in The idea here is to enable the UK both government and biotech I public to invest in innovation, much know I can be an effective voice for the same way as the French have the BioIndustry Association and I been invested in their biotech am really looking forward to sector in the past. The BIA will be working across the sector and with putting considerable weight behind government, academia and the this to encourage adoption by health service to enable bioscience policy makers. One Nucleus companies to succeed in the UK.‟ members may be interested in seeing the report once published in In terms of priorities, Steve the autumn.‟ acknowledges there are many but sees the following as issues - „Medicines and Healthcare particularly critical to members and products Regulatory Agency where he will be pushing for (MHRA) consultation on Early progress in the short term. Access Scheme - this is one
Steve Bates, CEO BIA
Steve Bates is the recently appointed Chief Executive Officer of the BIA and One Nucleus spoke to him on the eve of his full appointment on 1 September 2012. „The raison d‟etre of the BIA is as the voice for the sector, particularly in government, and we plan to continue to effectively represent the industry as a whole. I am lucky to be able to lean on my experience at Genzyme but also prior to that, working in UK government as special advisor for John Reid MP. A little known fact is I‟m the most travelled special advisor in UK government history, having worked in seven departments but most notably alongside Defence and Home Office which gave me unique insight into matters of animal licensing as well as terrorism. I also spent two years at the DoH, so altogether I have a real understanding for the “ins and outs” of Whitehall.‟
element of the government‟s Life Sciences Strategy proposal to boost the sector and a scheme the BIA will follow closely. We will be making a detailed response to the government‟s proposal after running workshops and full consultation with our members.‟ - „Similarly, the BioMedical Catalyst Fund – this is a new fund coming from government that will be used for the benefit of the life science community. The BIA has lobbied hard for many years for this and I am happy to take up the mantle and make sure that it is practically working for companies.‟ Continued overleaf
- „Animals in research – this means UK by the MHRA, DoH and Number working as a coalition not only 10 around adaptive licensing - how within the industry but outside with things might change and become
members. He also welcomes any opportunity to get back to the Cambridge Fenlands, with fond memories of his undergraduate days at Girton College and where he moonlighted as a DJ on what was then CNFM103 radio. Steve points to other ex-students of Girton College as important contributors to the biotech policy debate including George Freeman, academics and charities to easier for the life science sector. government advisor on Life continually review that the public Catching that wave and navigating Sciences and Phil Hammond, GP, have a realistic and sensible to a successful outcome will be all comedian and regular contributor understanding of the role of important for our industry.‟ on all things medical to Private Eye. animals in research for new „I‟m no George Freeman, or Phil medicines.‟ Steve is keen to stress that he is no Hammond but hopefully sit stranger to One Nucleus and its Looking more to the future, Steve members having spoken at many says „it‟s such early days in the role events in his previous role as senior and I am still developing my director external affairs at Genzyme thoughts.‟ What he can say though and as an expert in market access is „there is much regulatory debate and policy. He sees his on how things might change not appointment as a great chance to only at a European and continue and deepen his International level but here in the relationship with One Nucleus
‘I’m no George Freeman, or Phil Hammond but hopefully sit somewhere in between!’ Steve Bates, Chief Executive BIA
Imperial College London Collaboration will Aid Malaria Vaccine Development Imperial College London is collaborating with the PATH Malaria Vaccine Initiative (MVI) and the International AIDS Vaccine Initiative (IAVI) to guide the selection and prioritisation of malaria vaccine candidates. The collaboration will create a new central „reference lab‟, measuring, under standardised conditions, the capacity of different vaccine candidates in human clinical testing to elicit an immune response aimed at protecting against deadly malaria parasites.
Human Immunology Laboratory (HIL) at Imperial College London One obstacle to comparing the cell- refined and validated specific tests, mediated immunity elicited by or assays, that measure vaccinedifferent malaria vaccine candidates induced, cell-mediated immunity. has been the lack of uniform validated techniques and processes „These tests can used by different laboratories to provide quantitative evaluate T-cell immunity. In an information, such as effort to identify a more consistent how many cells understanding of how multiple responded to the vaccine candidates were performing vaccine, along with at a cellular level, IAVI and its qualitative
information, such as the different cell types that were stimulated,‟ said Professor Gavin Screaton, Head of the Department of Medicine at Imperial College London. „Both types of information can be important in determining the power of the overall vaccine-induced immune response.‟ „We‟re delighted to be hosting this work at Imperial, which builds on our longstanding fruitful association with IAVI,‟ he said. „We‟re also looking forward to working more closely with MVI as part of our commitment to vaccine research and international health.‟
AstraZeneca and Bristol-Myers Squibb Expand Diabetes Alliance Nick Dunscombe, Leader , Global Alliance Management Centre Of Excellence at AstraZeneca
In August AstraZeneca made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a whollyowned subsidiary of Bristol-Myers Squibb, in connection with the expansion of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb. AstraZeneca also informed BristolMyers Squibb of its intention to exercise its option to acquire certain additional We were delighted to announce in governance rights over key our Spring Newsletter AstraZeneca strategic and financial decisions as the first large pharmaceutical regarding Amylin‟s portfolio. The company to engage in our One rights to this option will become Nucleus Partner Programme. Since effective once the applicable antithen the Company has trust and competition approvals are strengthened its leadership position received by AstraZeneca. Upon the of successful alliance in diabetes. exercise of the option an additional payment of $135 million will be AstraZeneca and Bristol-Myers made to Bristol-Myers Squibb. Squibb Company announced in June that Bristol-Myers Squibb Simon Lowth, Interim Chief would acquire Amylin Executive Officer, AstraZeneca, Pharmaceuticals Inc for said: „The broadening of our approximately $7 billion, and that diabetes collaboration with Bristolfollowing this acquisition, Myers Squibb is another important AstraZeneca and Bristol-Myers step towards creating a leadership Squibb would enter into position in the treatment of a collaboration arrangements, based disease that is reaching epidemic on the framework of the existing proportions in many areas of the diabetes alliance, regarding the world. We are looking forward to development and commercialisation working with the team at Amylin to of Amylin‟s portfolio of products. build on their success and Profits and losses arising from the maximise collaboration would be shared AstraZeneca‟s equally. and BristolMyers Squibb‟s
combined capabilities to make Amylin‟s innovative treatments available to diabetes patients across the world.‟ Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb, said: „The completion of our acquisition of Amylin and the expansion of our diabetes alliance with AstraZeneca will increase and strengthen our innovative portfolio of diabetes medicines, extending its reach across the spectrum of treatment options. We are pleased to have the opportunity to work together to build on the innovative portfolio, state-of-the art manufacturing facilities and dedicated customer focus that the talented people at Amylin have created.‟ Nick Dunscombe, who heads up the Alliance Management Centre of Excellence at AstraZeneca, responsible for the proactive management of our partnerships and the sharing of best practice, added: „Signing the deal is just the beginning and the success of the ongoing partnership is our key priority. At AstraZeneca we are keen to continuously improve our Alliance Management capabilities, as an example we conduct annual surveys, with our partners known as “health checks”, and also actively apply learning / best practice from our partner. In this way we also ensure that we are meeting our partners‟ needs and delivering upon our joint commitments.‟
A Fresh Approach to Communications Sarah Jeffery, Project Director Zyme Communication
Zyme Communications Ltd (Zyme), the public relations and marketing agency specialising in the life science sector, has had a particularly busy last quarter. New client wins have included MRC Technology, AbD Serotec and Cytoo, the new Zyme website has been launched (www.zymecommunications.com), and the company exhibited for the first time at the ELRIG Drug Discovery 2012 conference. On the back of this growing business success, Zyme has recently announced the appointment of Sarah Jeffery to the post of Project Director. Commenting on her new position, Sarah said: „My first project having recently joined Zyme is working with One Nucleus on this, the Autumn edition of the One Nucleus Newsletter. We support Harriet and her team as communications advisors and editors of the biannual newsletter which goes to 8,000 recipients internationally. Nothing like being thrown in at the deep end, but it has been a great opportunity to very quickly reacquaint myself with this vibrant cluster. Within just a few days I had interviewed Thomas J. Sommer, President of MassMEDIC, the largest regional medical device association in the United States, and gleaned a little known fact from Steve Bates, the BIA‟s new CEO on the eve of his first official day in post.‟
Harriet confirms „Our view here at One Nucleus is that relationships are built on mutual trust, respect and proven delivery. We have known Lorna, Zyme‟s MD, for a number of years and she and her team at Zyme are the natural partner of choice to be involved in our biannual Newsletter‟s creation‟. As a marketing and communications specialist, Sarah has over 20 years‟ experience leading growth, brand awareness and strategic initiatives for healthcare companies – from life sciences through to clinical practice, most recently as Head of Public Relations & Communications for The Practice PLC. „What really attracted me to Zyme was the breadth of its service offering and refreshing approach to business. Zyme is not only a PR agency but has extensive experience in marketing and design, which really plays to my strengths in delivering integrated campaigns both in house and for
clients. I had worked with Lorna previously and I was absolutely delighted to be approached to join the team.‟ To find out more, visit zymecommunications.com or contact email@example.com
A Focus for Life Sciences Activity in the UK Capital Novel cancer therapies firm, Spirogen, has joined London‟s fastest growing life science, healthcare and technology hub. The Queen Mary BioEnterprises (QMB) Innovation Centre, London‟s first completely new build facility for early stage start-up and follow on life sciences and biotechnology companies, announced the chemistry division of Spirogen as their newest tenant in July.
significant impact as we progress our various programmes and technologies. The ability of QMB to provide office space alongside laboratory space, which has been tailored for our specific needs, was a key factor in our decision to come here.‟
The QMB Innovation Centre is able to provide both conventional incubator and grow on space in London. Through the combination One Nucleus member Spirogen, of its initial base build founded in 2000, has one oncology infrastructure design and the drug, SG2000 currently in Phase II subsequent overlay of commercial clinical trials, a platform technology lab fit-outs, QMB can offer both for highly potent Antibody-Drug chemistry and biology category 2 Conjugates (ADC), and laboratory and office suites. This partnerships with Genentech, Celtic flexibility allowed Spirogen suites to Therapeutics and ADC be equipped with an air extraction Therapeutics. system incorporating eight low electricity consumption chemistry Dr Chris Martin, CEO of Spirogen fume hoods, which were installed in said: „The state of the art facilities a joint design programme with offered by QMB will have a QMB.
Ramsay Richmond, Executive manager of QMB commented: „We are very pleased that Spirogen have found with us, modern and affordable commercial chemistry labs inside London. Spirogen had specific discovery chemistry needs, but the Innovation Centre was able to accommodate these in a joint fitout, illustrating the strength of a modern, easily reconfigurable building. This validates the faith of both funders, QMUL and the GLA, in supporting an infrastructure intensive building inside London.‟
Building the Community at Stevenage Bioscience Catalyst Against a backdrop of stellar performance from Team GB at the London 2012 Olympics, Stevenage Bioscience Catalyst (SBC) has been building a thriving community over the summer. In addition to the exciting news in June that Cambridge University will be locating a centre of innovation at SBC, the facility now houses several entrepreneurs and startups, complemented by virtual tenants and Aptiv Solutions. A key ethos for SBC is to pull closer together the constituent parts of the UK life sciences innovation ecosystem, and the University's desire to tap into this validates the model. The University was attracted
to SBC by its open innovation approach and access to drug development expertise from GlaxoSmithKline and other stakeholders, tenants and partners. You can hear more from the University at the inaugural Stevenage Bioscience Catalyst Open Innovation Summit, which is taking place on 15 November 2012. There's a 20% registration discount for One Nucleus members via www.eventbrite.com/ event/3821959584?ref=ebtnebtckt
Social Media - The black hole of time, unless you know what you’re doing!
Mike Gilham, Sales Director First Sight Media
main difference between these approaches is that tactical online campaigns deliver „a short-term fix‟, whereas strategic, digital marketing campaigns deliver long-term benefits, and allow planned inclusion of video and website strategies. Once a core strategy is established, tactical campaigns may be added for short-term benefit and as a fast flexible approach to tackle new topics. The Art of War master Sun Tzu once said „Strategy without tactics is the slowest form of victory however tactics without strategy is the quickest way to defeat‟. Social media can be your commercial friend or foe. Applied correctly, as part of a digital marketing plan, it can deliver exceptionally cost effective and quantifiable results. However, without careful planning, it can suck hours from your day and achieve nothing. Firms have achieved success through the use of social media, website or video marketing campaigns, but few companies have grasped the competitive advantage to be gained from using all three together. A successful blend of social media, website and powerful video marketing can deliver synergistic commercial benefits. Life science firms are reported to engage in tactical on-line campaigns but few have demonstrated they have the inhouse skill set to create and execute strategic campaigns. The
First Sight Media has the expertise to help life science firms develop a
strategic digital marketing plan combining these three marketing tools, to help companies to get ahead of their competitors. Video marketing can include capturing and streaming, live webinars, with live Q&A from edelegates, on-demand webinars, corporate videos, capturing exhibition and conference plenary speakers and video clips for inclusion within the client website. Recent clients include One Nucleus, Roche, Boehringer Ingelheim, and British Equine Veterinary Association. For more information please contact Mike Gilham at First Sight Media on 0800 072 8753 or firstname.lastname@example.org. Alternatively please visit www.firstsightmedia.co.uk
UCB Encourages Tomorrow’s Medicine Discoverers UCB opens its labs to pupils and hopes to ignite a passion for science and in turn generate more UK science graduates There can be few GCSE or A-level students who reply when asked about career plans, „I‟d like to be a medicine discoverer,‟ but through a new scheme between UCB and local schools that may be about to change.
The drug company UCB, renowned for its central nervous system and inflammatory treatments, opened its research laboratories to around 30 science students in July and plans to send UCB scientists out to
teach at local schools. The company has its UK headquarters in Slough, Berkshire, where it also hosts its world centre for research into immunology. Some 400 scientists work at the centre looking at conditions such as rheumatoid arthritis, lupus and osteoporosis. UCB invests heavily in R&D, especially within the UK where they are one of the top R&D investors. But cash isn‟t the only way to invest, and as part of UCB‟s long term commitment to UK life sciences the company is keen to boost science skills and science education and help secure a positive environment for research and development. To display this commitment, UCB
launched „Work In Science Week‟ where GCSE and A-level science students were immersed into the world of industrial research science, in a hands-on interactive environment. The UK has a long history as a world leader in many fields of research, producing over 10% of global scientific output with only 1% of the global population. But despite a wave of educational reforms in the UK over the past decade, fewer school pupils are choosing to study science and maths beyond the age of 16. UCB hopes that this project can encourage young scientists to carry on a very British tradition.
BioFocus Signs Two New Collaborations, Expands Drug Discovery Offering and Enhances Screening Library BioFocus, the integrated drug discovery partner based in Cambridge, UK, has signed two new collaboration agreements with Japanese company Ono Pharmaceutical in recent months. The first focuses on discovering novel targets in the field of allergic diseases including atopic dermatitis and bronchial asthma. The second agreement, announced in early September centres on discovering novel drugs in the field of CNS disorders. Adding to its drug discovery capabilities, BioFocus has signed a strategic alliance with Activiomics, allowing BioFocus to offer the company‟s proteomics services to its customers to improve identification of novel targets for
drug discovery and biomarkers for diagnostics. Activiomics proprietary technology, TIQUAS (Targeted Indepth QUAntification of cell Signaling), provides valuable insights into which proteins or pathways have been activated following a cell signaling event, information that is generally not accessible using conventional expression analysis. The technology has application in a range of therapeutic areas including oncology, inflammation and metabolic disease. A further development for the company, as part of its strategy to maintain its position as a leading provider of screening services, was the decision to select Titian Software‟s industry-leading Mosaic
sample management software to provide fast and easy access to BioFocus‟ 900,000 compounds, one of the largest HTS compound collections of any CRO in the world. Kate Hilyard, VP Biological Sciences of BioFocus commented, „Further developments in infrastructure and equipment are in the pipeline to support what will become a single, fully consolidated screening centre at our Chesterford Park site by the end of 2012.‟
Engineering Design in Cambridge Argon Design is a design services consultancy based in Cambridge, UK, providing high technology product design and development for their clients, which range from entrepreneurial start-ups to established multinational organisations. With a focus on electronic product design, including both hardware and software disciplines, Argon Design have particular expertise in the areas of signal processing, image and video processing, multimedia, networking and in solving complex algorithmic problems. The Company was founded in 2009 by serial entrepreneurs Steve Barlow and Alan Scott, who between them have over forty years of experience in running design consultancy businesses. Being based in Cambridge allows Argon Design to attract and recruit the best „Google quality‟ engineers, both from the local supply of graduates and from further afield
within the UK and Europe. For projects that require a wider range of disciplines such as PCB manufacture and assembly, mechanical design or product styling, Argon Design can draw on a network of trusted partner companies many of which are based in the Cambridge area.
to bring best in class design skills and technology to bear for each client project.‟
Client projects typically include a mixture of design functions covering some or all of the following areas – requirements specification, system architecture, analogue and digital board level Argon Design uses its experience of design, embedded and application managing the product development software, RTL design, FPGA design, process to assemble the strongest processor design, algorithm possible team of specialist design development, signal processing and and manufacturing resources image processing. In only three according to each client‟s priorities. years, Argon Design has established a portfolio of Argon Design‟s CEO, Alan Scott, international clients, including explained: „Argon Design is companies in the USA, Far East and delighted to join the One Nucleus Europe. Partner Programmme. We have long been enthusiastic advocates of For further information visit partnering as a means of building a www.argondesign.com or call Alan network of complementary Scott on 01223 422 355. engineering skills across a range of disciplines. This approach allows us
Syne qua non - Leading the way in Data Management, Statistical Reporting and EDC Syne qua non (SQN) is a UK based leading data management, statistical reporting and electronic data capture (EDC) specialist service provider and is recognised in helping its many customers to achieve their product development goals through innovative, quality based technology and processes, supported by an experienced team of professionals. SQN is a long-term trusted partner of many global pharma, biotech, medical device, consumer health and animal health focused
supporting local or international trials where required.
companies as well as academic and health care providers. Together with other specialist CRO partners, SQN also provides fully integrated clinical services capability
SQN recently announced a significant enhancement to their EDC and Clinical Trial Management System, Syne-clin. A senior clinical research professional described Syne-clin as delivering the ease of use and functionality that many envisaged EDC should have delivered when it was first introduced decades ago. Continued overleaf
Member News SQN have incorporated the wishes and feedback from many involved in clinical research, involving hundreds of clinical trials hosted in many countries. Rapid study start up coupled with innovative PDF based eCRFs with a paper look and feel, simplify the data collection process. Advanced real-time data validation and flexible drill down reporting through innovative project dashboards are additional reasons why the system is being received so positively across the industry.
October 2012 A number of One Nucleus member companies are working with SQN on a range of projects ranging from development consultancy through to full service clinical trial management, data management, EDC, statistics and reporting. Preferential rates are available for One Nucleus members. If you are interest in hearing more about SQN and how they might add value to your development planning then they will be happy to discuss your needs with you.
For more information please Contact Karen Grover on 01379 644449 or email at email@example.com. Alternatively please visit www.synequanon.com
Horizon Partners with Bayer, Domainex and ATCC Horizon Discovery announced in July that it is collaborating with Bayer Pharma AG, using its precision genome editing technology, GENESIS, to develop preclinical cell line models to support Bayer‟s oncology research
Chris Torrance, CSO, and Darrin Disley, CEO, Horizon Disocvery
Kam Dhaliwal, Director of Business Development, Horizon, said: „We look forward to leveraging our genome engineering expertise to assist Bayer in finding novel potential drug candidates to address cancer. We are delighted that Bayer selected Horizon to collaborate on its drug discovery programs, in recognition of our oncology disease expertise.‟
Profiling of Domainex‟s lead TBK1/ IKKε dual inhibitor molecules against these cell lines will enable identification of the effect of individual mutations on drug activity and resistance, and prediction of which patient subgroups will respond. This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.
Aside from research collaborations, Horizon recently announced an Horizon also agreement with ATCC, the recently American Type Culture Collection announced its (ATCC), under which ATTC has noncollaboration with exclusive global licensing and Domainex, to distribution rights for panels of support Horizon‟s X-MAN cell lines. The Domainex's lead agreement covers distribution to optimisation ATCC‟s academic and not-for-profit oncology customers as a part of or in programme, TBK1/ conjunction with ATCC Tumor Cell IKKε, which is Panels, for non-commercial being run in research only, and excludes conjunction with distribution in Japan or distribution the Institute of of X-MAN isogenic cell lines in Cancer Research, isolation. London. Horizon will support the programme by and development programs. The profiling a number of lead aim of the collaboration is to deliver compounds against a panel of high quality cell lines that more its X-MAN isogenic human cell accurately model the diseaselines modeling the mutations relevant mutations found in human found in cancer cells. tumors.
Selcia Exploits In-house IP with Demerger Move the end of July.
Simon Saxby, CEO Selcia
Selcia Limited, the globally active contract research organisation (CRO), announced the demerger of all internally generated intellectual property into two new companies at
CEO, Simon Saxby, commented: „The move will enable us to exploit internally generated IP efficiently and remain focussed on our successful core CRO business. Demerging our mitochondrial dysfunction and novel non-cyclosporin cyclophilin inhibitor molecule programmes into Mitopharm, and our anti-infective programmes into Selcia Pharma, will also allow us to raise investment capital more easily. We are in discussions with a number of potential partners and expect to sign at least one licensing agreement in 2012.‟
The first half of the year has seen activity across both of Selcia‟s operations: 14C custom radiolabelling and integrated drug discovery. The Radiolabelling Division celebrated 20 years of radiosynthesis at the Ongar, UK headquarters while the Discovery Division continued to develop and promote its CEfrag drug discovery platform and signed agreements with a number of pharma partners, including Heptares.
Cellzome Spins Out as Autophagix
Autophagix is based in the Mansion at Chesterford Research Park and will focus on developing small molecules that enhance autophagy. „What is becoming clear is that the process of autophagy can often go wrong, either because of your genes, your environment, or most likely a combination of both,‟ said
Dr Alan Watt, CEO of Autophagix. „Modulating autophagy has great potential for the treatment of a number of inflammatory diseases‟.
their extensive drug discovery and development experience by offering to manage the progression of molecules for other organisations.
The Autophagix Team
As a part of the acquisition of Cellzome in May this year, GlaxoSmithKline announced that it intended to facilitate the creation of a spin-off company, which would hold the rights to certain of Cellzome‟s assets that GSK itself did not wish to progress. Cellzome‟s activities at its Chesterford Research Park laboratories have now ceased, but in the meantime a small team of drug discovery scientists previously with the company have formed a new venture, Autophagix, to exploit these assets.
In addition to seeking funding to develop the Cellzome assets, the Autophagix team is also looking to capitalise on
Imperial Innovations Leads investments in PsiOxus Therapeutics and Cell Medica Significant healthcare investments were made by Imperial Innovations Group in July. PsiOxus Therapeutics, a development-stage biotechnology company that is using non-traditional approaches to develop novel therapeutics for cancer and wasting diseases, raised £22 million in a funding round led by Imperial Innovations alongside Invesco Perpetual, SR One and Lundbeckfond Ventures. PsiOxus will use the funding to advance the clinical development of ColoAd1, a potent, broad-spectrum anti-cancer therapeutic capable of selectively destroying tumour cells at minute concentrations.
Cell Medica, a clinical-stage cell therapeutics business, raised £17 million from Imperial Innovations, Invesco Perpetual and the Cancer Prevention & Research Institute of Texas. Cell Medica, which is developing technology based on the selection, activation and expansion of immune cells, specifically T-cells, to prevent and treat a range of diseases will use the funds to advance its Cytovir immunereconstitution products towards commercialisation, and to advance clinical development of its Cytorex EBV cancer therapy for the treatment of Epstein-Barr Virus related cancers.
Imperial Innovations builds and invests in technology and healthcare companies based on research developed at or associated with Imperial College London, Cambridge University, Oxford University and UCL. The investment group is based in London, with offices in Cambridge at ideaSpace and the Babraham Research Campus.
TTP Labtech’s comPOUND is at the Heart of the University of Nottingham’s Managed Chemical Compound Collection The University of Nottingham‟s Managed Chemical Compound Collection (MCCC) offers rapid access to more than 100,000 diverse drug-like small molecules for high throughput compound screening. This fully automated, state-of-theart facility is provided by TTP Labtech‟s comPOUND sample store and comPILER tube-to-plate processing system. This facility is key to the University‟s drug discovery research and to provide services to its pharma/ biotech industry partners. Prof Peter Fischer, Director, Centre for Biomolecular Sciences, University of Nottingham, commented, „Worldwide pharmaceutical companies are turning to academic partners to
system that would increase throughput, maintain long-term compound integrity, improve reliability with complete inventory control and unattended operation‟, he continued.
support compound screening for drug R&D. The long-term vision is to provide a unique compound collection attractive to academic and pharma partners – especially SMEs without their own collections‟. „We were looking for an integrated compound storage and handling
TTP Labtech‟s comPOUND and comPILER form a compact and secure modular system that minimises the initial investment in capital equipment, yet still allows you to expand library size and throughput when required.
QPS Acquires JSW Life Science, Leading Specialists in CNS Diseases, to establish QPS JSW whose linearly integrated core competencies include: DMPK Toxicology Bioanalysis Translational Medicine Early Stage Clinical Research Phase II–IV Clinical Research The acquisition of JSW greatly extends QPS‟s capabilities to address new, as well as established drug targets, in the CNS space. Laboratories and testing facilities are located in USA, Europe, India and Pacific Asia. JSW Life Sciences (JSW), the largest independent CRO in Austria, performs both preclinical and phase II-IV clinical research. Over more than a decade, the preclinical group‟s formidable experience has focused on drug development for neurodegenerative diseases. JSW‟s
reputation in the CNS field is For further information please further enhanced by its capabilities contact firstname.lastname@example.org in preclinical efficacy studies and visit www.qps.com including in vitro molecular and cellular analysis, proprietary in vivo transgenic mouse and rat models, and their associated analytics. QPS is a GLP/GCP-compliant CRO
ICON Announces Plans to Expand Hospitalbased Presence for Translational Medicine ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced plans to further expand its UK hospital-based presence on the Manchester Royal Infirmary Campus. ICON has secured a 40,000 square foot pre-let at Citylabs, a newly developed biomedical centre of excellence which was formerly the Manchester Royal Eye Hospital.
transitioning into the new, larger Citylabs facility, currently targeted to open in Q4 2013. Along with ICON's Translational Medicine Research Centre, Citylabs will feature biohealth organisations, including the Central Manchester University Hospitals NHS Foundation Trust, The University of Manchester and other commercial research organisations.
„We are pleased to be expanding our early phase ICON currently operates a state-of- development services the-art, hospital-based Clinical through the establishment of Pharmacology Unit on the a Centre of Excellence for Manchester Royal Infirmary Translational Medicine in Campus, where it will continue to Citylabs,‟ commented Dr. run its Phase I operations until fully Mario Rocci, President, ICON
Development Solutions. „This expansion will enable ICON to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.‟ For further information please visit www.iconplc.com
Promega Develops NanoLuc Luciferase for Advanced Reporter Assays Promega recently launched NanoLuc, a novel luciferase that is smaller, brighter, and more versatile than any previously available bioluminescent enzyme. Its attributes provide new capabilities in reporter assays with potential in biologically complex applications that require greater sensitivity. NanoLuc technology includes a novel substrate, furimazine, developed by Promega organic chemists and a unique enzyme developed by Promega researchers using directed evolution techniques. Its unparalleled small size allows for enhanced viral delivery and protein fusion applications, and it is easily secreted from cells. The enzyme is two orders of magnitude brighter than either firefly (Photinus pyralis) or Renilla reniformis luciferases resulting in better performance in hard to transfect
cells. NanoLuc also demonstrates outstanding performance in more physiologically relevant models including complex biological samples.
address the application needs of a 'next-gen' genetic reporter. This includes NanoLuc-PEST (NlucP), which closely couples protein expression to changes in transcriptional activity and increased signal-to-background ratios. For a secreted reporter, a NanoLuc Luciferase construct has been prepared by fusion to an N-terminal secretion signal (secNluc). Using the Nano-GloT Luciferase Assay Reagent, luminescence is linear over a 1,000,000-fold concentration range with a signal half-life ≥2 hours.
With add and measure simplicity and a stable signal, NanoLuc Luciferase can be scaled from benchtop to high-throughput screening applications with no modifications. Promega has developed twelve plasmid versions of NanoLuc Luciferase, to
Recent Developments at Pharmidex Pharmidex, a CRO delivering CNS capabilities for application in and ADMET solutions to its clients, CNS and oncology studies. has had a number of developments recently. In June 2012, Pharmidex Pharmidex is involved in a number expanded its business development of new collaborations: activity by securing offices at the London Bioscience Innovation The Company was successful as Centre. a partner in two awarded FP7 grants. One of these grants is The Company is increasing its infor the BIOtrachea project, house capabilities: working with University College London and 12 Establishing a zebrafish facility other partners in collaboration with Evotec and across Europe the Royal Veterinary College. for the Expanding its service offering by replacement of organs using acquiring bio-imaging
synthetic materials. The second, „Imaging of Neuroinflammation in neurodegenerative diseases‟, is with 27 partners from centres of excellence across Europe and UK. In August 2012, Pharmidex was awarded a Biomedical Catalyst feasibility award together with Hypha Discovery.
MRC Technology Launches Antibody Engineering Service and Signs New Collaborations with Major UK Academic Research Institutes MRC Technology, based in London, has launched its fee free Antibody Engineering service for humanisation of antibodies. The service capitalises on CDR grafting technology developed at the MRC, and proprietary tools to deliver the optimum antibody configuration. Other engineering services offered by MRC Technology include affinity maturation and biophysical characterisation.
antibody engineering projects. The team has already humanised more than 50 antibodies, and its development work has delivered two marketed drugs (Tysabri and Actemra), with a further six, including Vedolizumab, in clinical trials and another two in preclinical studies.
Mary University of London (QMUL). The QMUL projects will exploit Gprotein coupled receptors (GPCRs) identified as effectors of endogenous resolution of inflammation, with the aim of developing therapeutics for e.g. chronic inflammation of the joints or vascular inflammation, with fewer side effects as they mimic MRC Technology has also launched the way the body naturally resolves several collaboration projects within inflammation. the past few months, including a The Antibody Engineering service is project with the University of carried out by MRC Technology‟s Warwick to develop inhibitors of BioTherapeutics team, part of MRC inwardly rectifying potassium Technology's Centre for channel kir7.1, for the treatment of Therapeutics Discovery (CTD) postpartum haemorrhage, and two which works on early stage small new collaborations with the William molecule drug discovery and Harvey Research Institute, Queen
Good News for MedImmune erythematosus and ulcerative colitis.
MedImmune, the global biologics arm of AstraZeneca, is at the forefront of groundbreaking biotechnology research and development. MedImmune programmes now make up over 40% of AstraZeneca‟s overall pipeline, the MedImmune pipeline having grown from 40 assets in 2007 to more than 120 candidates currently.
In July, it was announced that the UK is planning to introduce routine flu vaccination for all children between the ages of two to 17 from the autumn of 2014, with MedImmune‟s intranasal flu vaccine, FluMist (Fluenz in Europe) as the vaccine of choice for the programme. The decision to offer such a routine programme for children is the first of its kind anywhere in the world and is expected to bring benefits, not only for vaccinated children, but also in In April, an innovative collaboration reducing serious illness and deaths was announced between in the wider population. MedImmune and Amgen to codevelop five monoclonal antibodies from Amgen‟s clinical inflammation portfolio. The collaboration has the potential to benefit the lives of patients suffering from a range of conditions, such as, asthma, Crohn‟s disease, psoriasis, psoriatic arthritis, systemic lupus
Advertising Discounts now available to all One Nucleus Members Steve Simmonds, Advertising Sales Manager OUP
spanning a wide range of subjects including bioscience, biology, botany, genetics, ecology, and more. Highlights include Nucleic Acids Research, Human Molecular Genetics, Bioinformatics, Protein Engineering Design & Selection, Annals of Botany, and Molecular Biology and Evolution, among others. OUP‟s highly cited, high-impact and prestigious medical journals include 68 titles across a variety of fields from oncology, infectious diseases, cardiology, and nephrology, to reproductive medicine, rheumatology, anaesthesia and geriatrics. Highlights include the Annals of Oncology, Clinical Oxford University Press (OUP) is Infectious Diseases, Journal of offering One Nucleus Members 10% Infectious Diseases, and the off all advertisements, in their Journal of Antimicrobial highly respected Life Sciences and Chemotherapy, among many Medical journals. others. OUP publishes over 280 journals, 50 of these within Life Sciences,
research settings. Also, books content published by OUP can be repackaged to suit your educational and promotional needs in both print and online. Articles, or book chapter reprints, can be useful promotional tools. To get critical research and clinical findings direct to the professionals that need to see them, you could consider publishing a supplementary issue to a relevant journal. These meet the same editorial standards. To find out more about the above titles, or the advertising and sponsorship opportunities available in partnership with OUP, please contact email@example.com or visit www.oxfordjournals.org/corporate
OUP‟s journals appeal to those working in both clinical and
Amadeus Capital Partners joins One Nucleus
Amadeus Capital Partners is one of Europe's leading technology venture capital firms. Since its inception in 1997, the firm has backed nearly 80 companies in industries that include communications and networking
hardware and software, cleantech, medtech, computer hardware and software, media, and e-commerce. Amadeus manages funds with total commitments of £500m. Global businesses built by the firm include CSR plc (LSE:CSR), the leading producer of single chip bluetooth radios for short range connections, and Solexa Ltd, the developer of next generation genetic analysis systems, merged into Illumina, Inc. (ILMN) to create the world-leader in gene-sequencing technology. For more information, please visit www.amadeuscapital.com
Pierre Socha, Investment Manager, Seed Funds
Commenting on becoming a Silver member, Pierre Socha, Investment Manager, Seed Funds said, „Amadeus Capital Partners is pleased to be associated with One Nucleus which is a vibrant player in the European life science industry. With investment focus on medtech we foresee significant synergies and look forward to a high level of interaction with other members.‟
Quantifying Patient Segments is Key to Healthcare Innovation and Securing the Future of Healthcare The pharmaceutical industry is in a state of evolution. Many blockbuster drugs that have supported the industry well financially over the last few decades no longer have patent protection, allowing generic products to enter and de-value the market. The use of generic substitutes for branded products is being actively encouraged by the NHS to help reduce spend on drug treatments whilst enabling an ever growing number of patients to receive care. This will deliver some of the savings needed to fill the £10bn NHS funding gap by 2015. With increasing use of these generics, regulatory authorities such as the MHRA are now viewing these as the „standard of care‟, creating higher hurdles for any pharmaceutical company attempting to develop improved follow-on treatments that can be proven to be cost-effective to the healthcare system. Outlook This has driven R&D functions of many pharmaceutical companies and Biotechs to narrow their focus and begin to look at niche opportunities in disease areas previously overlooked as too challenging or not having enough patients to deliver a reasonable return. These opportunities will be looking at very specific patient criteria that correlate with the planned treatment and reflected in their eventual marketing authorisation and indicated use if successful. Thus, it is essential for the industry to have a better understanding of the patient population for a particular disease, and this needs to go deeper than basic incidence or prevalence data currently used today to more detailed subpopulations that highlight specific attributes, co-morbid conditions and risk factors.
With this knowledge, treatments can be targeted toward patient profiles most likely to benefit from the new treatment, thus improving chances of a successful outcome. This sets the scene for more refined clinical trial plans with reduced numbers of patients in the trial, reduction in overall costs and shortened development times for new treatments. From a NHS perspective, this detailed patient population information is ideal when reviewing new healthcare technologies to identify the patient group that will benefit the most and set a suitable reimbursement price. Solution Basic information already exists from various patient groups, such as the Alzheimer‟s Association, for prominent and well-understood disease areas. However, this is inadequate for a large number of diseases and disorders where information is limited. To gain more relevant patient detail, information needs to be gathered from the many patient registries and epidemiology studies that look specifically at clinical attributes, risk factors and outcomes. A new resource, the Epiomic Segmentation Database, has emerged to provide this missing insight and form the building blocks of patient segmentation. It is a web-based tool for healthcare professionals who require more intimate understanding of populations affected by particular conditions. It offers a reliable, evidence-based source of patient populations that goes beyond basic prevalence to include essential conditions and patient attributes for over 120 diseases. For access to this tool or more information on the types of information it can provide, please
contact firstname.lastname@example.org or see our website www.epiomic.com For further information on Black Swan Analysis please contact email@example.com or see our website www.blackswan-analysis.co.uk
MEPC Sells Granta Park to BioMed Realty MEPC has sold Granta Park for a sum in the region of £127 million to the American biotech property firm BioMed Realty Trust, Inc. (NYSE: BMR). The acquisition will see BioMed take control of 472,200 sq ft of space including 11 buildings at the park, which is home to some of the world‟s foremost biotechnology and pharmaceutical companies. The sale is line with MEPC‟s continuing strategy of releasing resources to focus on its large scale, mixed-use Estates. Under
Rick de Blaby, Chief Executive of MEPC said: „Granta Park has been very important to MEPC over the last decade as a leading contributor to our financial performance, and we are delighted that such a prestigious science park asset is passing on to a discerning investor. Our strategy is the continual development of our national portfolio of large mixed used Estates by means of recycling capital from the relatively stabilised and mature assets. Focussing on the large mixed use Estates
science park it is today. The sale of this robust asset is very much part of our ongoing strategy of releasing resources to focus on the development and success of other large-scale Estates.”‟ Commenting on BioMed Realty‟s first international life science real estate investment, Alan D. Gold, Chairman and Chief Executive Officer, said: „We are extremely pleased and excited to announce our expansion of BioMed Realty‟s best-in-class property portfolio with this investment in Cambridge, the premier life science cluster in the UK and arguable all of Europe. The Cambridge market enjoys all of the critical elements that mark a strong, selfsustaining life science cluster, namely proximity to premier academic and research institutions, a highly skilled workforce, access to financial partners and a healthy portfolio of strong commercial life science organisations.‟
Kent Griffin, President of BioMed Realty added: „Granta Park provides an MEPC‟s management Granta Park presents a huge opportunity for excellent investment opportunity has grown into a leading science MEPC, as we know that we can with very attractive return potential park with 99.8% of units let. drive sustained financial consistent with our core business Tenants include MedImmune, PPD performance by applying our strategy – focused on highestGlobal, UCB Pharma and Vernalis proven management style: focusing quality real estate in core life (R&D). on customer care and developing science clusters and in close an in-depth understanding of our proximity to primary demand Cambridge has become the premier occupiers‟ needs.‟ drivers, including leading research centre for science in the UK and institutions. This recently globally, and the success of Granta „With our strong cash position, developed, amenity-rich 11Park has been a significant MEPC is also well positioned to building campus has attracted contributor to accommodating capitalise further upon bank world-renowned life science many of Cambridge‟s leading biodeleveraging in the UK market and, research organisations and includes pharma companies. Granta Park is with our established management additional development potential, now a world class science park platform, we will be seeking to enabling us to support their which offers a superb position acquire additional assets through continued growth and expansion.‟ within the heart of the Cambridge the cycle.‟ science cluster; it is on the right MEPC was advised during the side of Cambridge for London and Commenting on the sale, James agreement process by Jones Lang is in close proximity to the Dipple, Director at MEPC added: LaSalle on the investment sale, University of Cambridge, the „Since its opening in 1998, we have Berwin Leighton Paisner LLP Cavendish Laboratory, the successfully implemented our advised on corporate and tax law Laboratory of Molecular Biology, occupier focused management and BrookStreet des Roches on the Sanger Institute and the strategy to develop and grow property law. Babraham Institute. Granta Park into the world-class
One Nucleus News
What One Nucleus Does For You The One Nucleus Summer Social BBQ and Mojitos on the Banks of the Cam
On 27 June, One Nucleus hosted what has become an annual event at the DoubleTree by Hilton, Cambridge.
beautiful summer‟s evening and to network with friends and colleagues from the extended One Nucleus family.
In an idyllic location overlooking the punts on the Cam, 150 members attended the One Nucleus Summer Social. It was a fantastic opportunity to unwind on a
Thanks to the generosity of the DoubleTree, we were treated to some thirst-quenching Mojitos and PIMMs whilst tucking into a hearty barbeque.
For those of you interested in supporting or attending the Summer Social next year, please save the date now – Wednesday 19 June 2013. See you there! For more information please contact Philip@onenucleus.com
Wireless Sensing in Healthcare and Wellbeing On 25 September, One Nucleus, Cambridge Wireless and Sagentia hosted a one day conference entitled „Wireless Sensing in Healthcare & Wellbeing‟. With the rapid advancements in wireless technology and its increasing use in the healthcare realm, this event gave industry leaders the opportunity to share perspectives on current and future applications and address some of the technical, operational and ethical realities that lie ahead. An excellent line up of speakers included Sagentia‟s Senior Vice President of Medical, Mick Withers; Vice President of Surgical, Alistair
Fleming and Manager of Patient Care, David Pettigrew. They were joined by other industry leaders including: Professor Chris Lowe, University of Cambridge, Richard Curry, SEHTA and Sybo Dijkstra who is Head of the Hospital-toHome and Service Innovation Group at Philips Research.
discuss areas of collaboration and exchange opinions on appropriate next steps. The 70+ delegates had a valuable discussion and went away with new ideas and contacts. We will be following up on this one for some time!
The day started with a selection of For more information about the informative presentations on topics opportunities in this area, contact including Wireless Sensors in the Philip@onenucleus.com Healthcare R&D Environment; Assisted Living and the Remote Carer; Health Related Robotics; and the Future of Patient Monitoring. This was followed by a series of workshops in the afternoon, giving participants an opportunity to
One Nucleus News
One Nucleus Training Portfolio Gains Recognition from the CPD Institute In recognition of our commitment to offering good quality training to the Life Science sector, One Nucleus proudly became a Corporate Affiliate of the CPD Institute in June this year. This now means that One Nucleus‟s training courses count towards Continuing Professional Development (CPD) points / hours demanded by professional bodies. These points will contribute towards the 40 hours of CPD required of the individual for admission to the class of Fellow of the Institute.
months, including a Business Development Academy, a course in Change Management and workshops on Smarter Working.
One Nucleus‟s training portfolio is the largest of its kind in the UK and our tailored courses are constantly evolving. Listening to member feedback, we will be introducing some new material over the coming
One area which is growing in popularity is the option to take any of our courses „in house‟ with us bringing the course to you. Companies who have done this have benefited from training being
As always our trainers are selected not only for their high quality training skills, but also their knowledge of the sector. Many of them have firsthand experience in companies within the Biotech and Pharma industry, giving them the knowledge to gear the course structure and content to the ever changing challenges we face.
tailored to suit their own specific needs at a time and place to suit their busy schedules. If your company is committed to maintaining a highly skilled workforce, then look no further. For more information about training please contact me at Philip@onenucleus.com
One Nucleus Activities in Europe ABCEurope Conclusion After three years of exciting activities within a consortium of 13 of the most dynamic bioregions in Europe, One Nucleus is now at the end of its involvement in the ABCEurope project which finished in August 2012. As a leading partner, One Nucleus has been engaged in the development and delivery of several great initiatives, including: Five Biotechnology showcases allowing researchers from academia and commercial organisations all over Europe, a platform to present their innovative technologies in the fields of oncology, medical technologies, infectious diseases, e-health and diagnostics;
Five bioentrepreneur boot camps - held in different European locations, giving 69 entrepreneurs the opportunity to benefit from business specialist‟s expert opinion and feedback on how to improve their company operations; Three virtual business matchmaking events - involving a total of 62 companies from 11 different European countries in partnering meetings with potential new collaborators; A „tool of science‟ platform which lists European facilities and funding opportunities from 18 regions and provides new business opportunities for R&D companies and service providers.
Although the overall project is now complete, all these activities will continue so we will keep you posted on post-project actions. Our involvement in ABCEurope has been a great opportunity for One Nucleus to develop closer connections with other European bioregions. As some of you will be aware, we collaborated with Medicon Valley Alliance, and Stockholm-Uppsala Life Science on joint activities for our members at BIO2012 and we are in discussions with a number of European clusters about further information exchanges and collaborations for member benefit. For more information on One Nucleus‟ European activities please contact firstname.lastname@example.org
One Nucleus News
One Nucleus at AdvaMed 2012
I‟ve just hot-footed it back from my first visit to AdvaMed. For those of you who didn‟t attend, it took place in Boston this year, last week. The global healthcare industry is clearly experiencing fundamental transformation as it moves to a value-based business. With increasing demands from consumers for enhanced healthcare quality and increased value, healthcare providers (and payers)
Presidential election live debate) from two of CNN‟s liveliest commentators Paul Begala (left wing) and Alex Castellanos (right wing). I was expecting AdvaMed to be far larger – not quite of the scale BIO operates at but certainly one of those events where you need flat shoes, lots of energy and plenty of Red Bull! In fact I really liked the smaller nature of it - it was
positive response to the mission. UK medtech companies are accustomed to innovating in an environment focused on clinical and cost effectiveness. Taking costs out of the system is the competitive advantage that UK companies bring to the US market‟.
UK Companies at AdvaMed Some of the UK companies were part of the FutureHealth (the Health Tech and Medicines Knowledge Transfer Network organised) mission in collaboration with the Technology Strategy Board. 20 of the UK‟s most promising healthtech companies in the areas of stratified and regenerative medicine, diagnostic and assisted living technologies and related solutions. For more are clearly under pressure to exceptionally easy to navigate, to information check out: deliver better and more tangible meet the right people and to have www.futurehealthmission.com. The outcomes. This against a backdrop some very useful meetings both clear message from the group is of pressures to reduce costs and with old friends and new. The that the US market is vast and improve co-ordination means that organisers claimed around 2,500 varied and understanding and times have perhaps never been delegates and certainly the largest preparation are vital to your market more trying for those involved in AdvaMed to date. The UK entry strategy. Their top tips for the healthcare sector. representation was by far the working in the US health largest from overseas, with over 50 environment are: do your research; AdvaMed 2012 did a great job in UK companies taking part. prepare to network; be US-literate; addressing the above, with top According to Anne Avidon, USA Market Plan and Utilise resources quality panel sessions, CEO debates Sector Lead for Healthcare at UK (learn from other company‟s US and some critical political insights Trade & Investment (UKTI): „We experiences and talk with UKTI). (in advance of the first US were delighted to receive such a Continued overleaf
‘It (AdvaMed) was exceptionally easy to navigate, to meet the right people and to have some very useful meetings both with old friends and new’
One Nucleus News
‘One Nucleus has a formal (and tangible) relationship with MassMedic’
remember that One Nucleus has a formal (and tangible) relationship with MassMedic. I took the Messages from the Department AdvaMed: The Focus opportunity to catch up with their of Health For more information about CEO, Tom Sommer, who was AdvaMed and to check out a new proudly sporting his One Nucleus Earl Howe took part in a key panel set of industry messages that they pin-badge when we met! See Page during AdvaMed where he had have created, click on 3 for our interview with Tom. He is some hard hitting messages for the www.lifechanginginnovation.org. able to offer a soft-landing for our „standing room only at the back‟ The messages are supported by members looking to access the US audience. That: sample proof points (which can be market and we offer the same to Innovation has to be made core found in the messages document of his members. We also remain close business for the NHS; the accompanying toolkit). The to Susan Windham-Bannister, There is a need to make the emphasis being on: President of the Massachusetts Life NHS a more intelligent customer Science Center Delivering value for patients; with a greater dialogue with www.masslifesciences.com and to Improving health system business; the Governor‟s office – some of you efficiencies; may recall Governor Patrick‟s visit (in his opinion) there has never Contributing to economic growth to One Nucleus here in Cambridge been a better time for and leadership; UK last year when he delivered his innovators to engage with the keynote address in the UK on life Securing public policies that NHST; sciences in the presence of many of sustain patient access and He wants to create greater our members. We enjoy keeping continued innovation. consistency across the NHS; these links very much alive and Innovation is key to the future. One Nucleus Connections into working for our members. the US The panel (which included Guy Lebeau Chair of Johnson & Johnson For One Nucleus members looking to connect with the medical and Eucomed) all readily agreed that industry needs to be seen very technologies sector in the US, do
Harriet Fear, CEO One Nucleus, with Tom Sommer, President MassMedic
Talking of whom…..UKTI ran a mission to AdvaMed as well – with one of the top highlights being a dinner at the Massachusetts State House hosted by the new British Consul General Susie Kitchens and Lord Howe, Parliamentary UnderSecretary of State at the Department of Health. According to AdvaMed officials: „The gala dinner hosted by the Brits was the hottest ticket in town, with CEOs, investors and healthcare officials asking how they could get a seat at the table‟. Adds Anne: „The UKTI team worked tirelessly to ensure that the UK attendees maximised the opportunity to make new contacts and get deals done. One company announced it expected to get £1 million in future revenue as a result of introductions made at AdvaMed.‟ One Nucleus members in attendance included Sagentia, Piramal Discovery Solutions and Zoragen. The vibe was incredibly positive. The mission was also supported by Professor Sir Bruce Keogh, Medical Director of the NHS and a great opportunity for me to reconnect with Sir Mike Rawlins, the Chairman of NICE who retires next year and I‟ve known for far longer than either of us would care much as part of the solution, not to admit! just a supplier.
One Nucleus News
HR Special Interest Group (SIG) employees who are not performing or who are no longer needed - without their organisation being derailed in the process. Eleanor Freeman, Cambridge Employment Law
On the back of the Beecroft Report - an entrepreneur‟s perspective on how to set employers free - Vince Cable has just announced his plans to give businesses „flexibility and confidence in managing their workforce and to reduce employment law red tape‟. They include:
Many small employers can‟t justify employing a dedicated HR professional to deal with the human side of their business. Very often it‟s the Chief Executive‟s PA or Finance Director who gets „personnel‟ wrapped up in their brief. And even organisations which do have a sophisticated HR department need help keeping up to speed with continual changes in the law. One Nucleus members span this broad spectrum, but because they‟re all operating in the same sector have many personnel issues in common.
The subject of the next meeting on 18 October is a „Practical Perspective on Maternity and Paternity Rights - from risk assessment to return to work‟. This will be followed by our first meeting of 2013 on 30 January. The Government‟s proposed reforms may well be on the agenda. Sessions are run by Eleanor Freeman, a very experienced employment partner at CEL. Eleanor has a commercial background, having been an international rights manager at global publisher Dorling Kindersley for six years before qualifying and spending her early years as a solicitor in the City. That City experience and her subsequent practice in Cambridge – as a partner at Taylor Vinters before leaving to co-found CEL LLP in 2011 - mean Eleanor has a highly unusual combination of skills and experience on which to draw when advising clients … and a whole range of great stories. She is also steeped in the biomedical sector having made this her focus since arriving in Cambridge at the beginning of 2005.
„I‟ve been running the One Nucleus HR SIG sessions for a number of That‟s where the One Nucleus HR years and thoroughly enjoy them. SIG steps in. In conjunction with For me, it‟s all about members Cambridge Employment Law LLP, leaving meetings with a plan to the One Nucleus HR SIG runs deal with individual problems that Settlement agreements to help quarterly meetings over lunch, with may have been sucking up their time - and worrying them - as well end employment relationships in the opportunity to network with others dealing with HR in biotech as renewed confidence on how to a fair and consensual way; and pharma companies, and a deal with the tricky issues which Reducing the cap on seminar focusing on an issue crop up time and again. It‟s also compensation for unfair relevant to the sector. Participation great for me to be able to build dismissal claims; is actively encouraged, with no war long-term relationships with Streamlining employment story deemed too gory to share. practitioners outside the solicitor/ tribunals by making it easier for client nexus. I get to know people, judges to dismiss weak cases. Recent subjects have included „The how they like to work and the Elegant Exit – how to manage an culture of their businesses, as well Given these are all ways of making employee out of the business with as an inside track on what‟s it easier and less risky to fire minimum fuss and cost‟, and happening in the sector from the employees, it throws into sharp „Managing Absence - how to deal HR perspective.‟ relief what really concerns effectively with short-term, employers: managing, and persistent and long-term absence‟. Eleanor Freeman sometimes ultimately dismissing, Cambridge Employment Law
One Nucleus News
One Nucleus Support Suppliers One Nucleus currently has 50 Support Supplier Agreements (SSAs); 16 of these have been signed since March 2012 so as you can tell, this is an ever-growing list, with a wide range of suppliers wanting to offer services to our members. Importantly these benefits can be accessed by ALL our members. For the full list please see the Purchasing pages on the One Nucleus website or contact me at email@example.com or on 01223 896453.
New Support Suppliers Since March 2012 Company 365Force
Cloud Computing Services
Advanced Drving Techniques Ltd (ADT)
Driving Risk Management
Black Swan Analysis
Business Analysis and Marketing Support Services
Vacuum Pumps and Services
Active Temperature Controlled Containers
Health, Fitness and Wellbeing Solutions
Redundant Asset Management Services
Haseltine Lake LLP
Intellectual Property Services
Hyper Recruitment Solutions (HRS)
Journal of Visualized Experiments
Insurance and Financial Management
International Payment Systems
Specialized Print Ltd
Corporate Printing Services
Venture Market Intelligence
Venture Market Database
One Nucleus News
One Nucleus Facilities Management Don‟t forget that One Nucleus offers Facilities Management consultancy to members at a discounted rate. Richard Dickinson Director of Specialist Services, has 15 years‟ experience as a Facilities Manager and has worked for more than 20 years in the life science sector.
Richard provides project management for office and laboratory fit-outs and can help with equipment service contracts, maintenance contracts, cleaning contracts, utility bills, insurance, purchasing and budgeting. Currently working for Cantab Biopharmaceuticals he has previously consulted for a number of One Nucleus members on
various different projects including Astex Therapeutics Ltd, Pathology Diagnostics, Babraham Bioscience Technologies Ltd, Zoragen Biotechnologies, Spirogen Ltd and Fahy Gurteen Laboratories. For more information on Facilities Management please contact Richard at firstname.lastname@example.org or on 01223 896453.
Exploring the China Opportunity Alan Barrell, Björn Segerblom, Sir Paul Judge, Martin Garrett and Philip Kendall
growing faster than anywhere else in the world, and that by 2050, 45% of the Chinese population will be over the age of 65. That is compared to only 15% today. The healthcare needs of these people will be enormous.
On 17 September a delegation of 17 arrived in Cambridge for two days of events co-hosted by One Nucleus and Cambridge Cleantech, and sponsored by the Hong Kong Science & Technology Parks (HKSTP). The delegation included representatives of HKSTP, Hong Kong based companies and officials from Hong Kong and mainland China.
After the reception there was a dinner for 100 invited guests in the candlelit Hall at Magdelene College, where the diners were entertained
The main event was a conference at Cripps Court where 150 people, including some One Nucleus members learnt about the opportunities for Life Science and Cleantech companies in Hong Kong and China. One startling statistic is that China‟s ageing population is
For more information on the opportunities in Hong Kong and China, contact Philip at Philip@onenucleus.com
Peng Jimin, Senior Economist NDRC
A VIP reception gave the visitors a chance to meet the great and the good of the Cambridge CleanTech and Life Science communities. Guests included Sir Paul Judge, Alan Barrell, and Charles Cotton of Cambridge Phenomenon fame. There was also a special guest, Sir John Bradfield, the founder, here in Cambridge, of the first science park in Europe.
by Sir Paul Judge with his after dinner speech.
Speakers at the event included senior Chinese official Peng Jimin, Senior Economist from the National Development and Reform Commission (NDRC) in China and Janette Evans, Executive Director (Corporate Business) at Astrazeneca. AZ consider China to be the most important pharma growth area at the moment, for the reasons mentioned above.
One Nucleus News
Genesis Conference 2012: A step change in delegate engagement this year‟s Genesis a must-attend event. The conference, debate and showcase on the theme of „innovative strategies to bridge the R&D gap‟ will include: An opening plenary session, with keynote speakers setting the scene and identifying challenges from policy, early stage innovation, later stage growth and deal success perspectives;
One Nucleus and our Programme Partners, SCRIP Intelligence, invite executives from the global life science industry to register to attend the 2012 Genesis Conference, taking place in London‟s prestigious Queen Elizabeth II Conference Centre on Thursday 13 December. There is a great deal written about such topics and the need for greater efficiency in the discovery and development of new medicines, the increasing regulatory barriers, emerging markets, innovative deals, industry globalisation, CROs sharing risk, Government interventions and the lack of venture finance to name just a few of the challenges and opportunities facing today‟s life science executives. There are numerous conferences, webinars and speeches delivered that all provide a degree of facilitation for executives to learn from their peers, instigate alliances or present to investors. However, there are very few conferences for 650+ delegates that create and environment where each delegate can go away feeling they have had an education in the roadmap to success through a critique of their peers‟ deal making, business models and hearing others‟ future
visions of the industry‟s on top of the traditional 1-2-1 meetings, networking and experience. After more than a decade of success, Genesis is stepping up a gear this year. Our collaboration with Scrip Intelligence will provide pre-conference commercial intelligence by therapeutic area, design a programme format to give a global presentation of the
industry from a UK perspective and increase our reach to the top Pharma and investment executives to engage them in the debate. Genesis 2012 will be truly thought leading. Identifying and addressing the issues that really matter, with a programme that is educational, inclusive and provocative, making
Parallel leadership sessions, focused by therapeutic or technology areas, where case studies of deals, financings and collaborations will be showcased and debated. The 90 minute sessions will cover: CNS, oncology, infectious diseases, inflammation and respiratory disease, cell-based technologies in R&D, Alternative Therapeutics, Open Innovation and a UK Showcase debating
what the UK has to offer domestic and international life science businesses; A closing plenary debate and reception, where feedback from the day‟s sessions will inform panel discussions as we look to develop a „Roadmap to Success for 2013‟; Continued overleaf
One Nucleus News A VIP Stakeholder Reception – replacing the traditional gala dinner awards, this year we are reaching out to the executives from the wider healthcare field such as patient advocacy groups, NGOs, policymakers and NHS commissioning groups. We will be inviting their senior personnel as guests to the plenary debate and networking reception in order to encourage greater dialogue and collaboration between those groups with a role in delivering future healthcare. Not to mention:
Lab21, Medimmune, Merck, MS Therapeutics, Pathology Diagnostics, Pharmidex, Senexis, International exhibition TWI and Vision RT with more being The parallel sessions within Genesis added as the themes expand. are purposefully designed to map Join the expected 650+ delegates: on to the Life Science Leadership book your place at this unique Series themes we have launched forum today. Delegate rates start since their creation in 2011. This from just £195 + VAT (Exhibitor includes engaging our world class fees from £1,100 + VAT) and can advisory boards from those be booked now at themes, comprising senior www.onenucleus.com/genesis-2012 executives from the following organisations: AstraZeneca, For more information on Genesis BioMedical Partners, Cancer please contact Research Technologies, Eli Lilly, Tony@onenucleus.com EOLAS, Future Injection Technologies, GE Healthcare,
Pre-conference intelligence from SCRIP, to inform delegates and stimulate discussion A Welcome Reception at the recently refurbished Canada House, courtesy of the Canadian High Commission on the evening of Wednesday 12 December
Navigating members to the right information at the right time with the One Nucleus Dashboard Isn‟t it great when you attend a networking meeting, leadership event or conference and one of the speakers or other delegates gives you just the right information to help you steer a better course of action to address current problems. The reverse is true too, of course, when the conversation at that meeting seemed irrelevant at the time only to find at a later date the information would have been key and you are left scouring the depths of your memory to recall who it was that was speaking. Fear not! Our latest initiative, the One Nucleus Dashboard creates the virtual reality of making that earlier networking event available 24/7 to members facing the practical challenges of managing a growing
life science business. To be launched in the near future, the Dashboard will be a one-stopshop helpline for easily accessible advice from selected experts across a variety of specialised areas. These specialist areas will include: Commercial Intelligence; Corporate and Commercial Law; Executive Recruitment and Interim Support; Facilities Management; IP Strategy; Logistics; Marketing and Communications; National and EU Grant Funding. Overall the Dashboard allows for better and more timely sharing of
expertise between members through an online enquiry function directed straight to the appropriate expert who will provide a timely answer direct to your inbox. This will allow members to seek the sort of rapid expert guidance you would expect to find when meeting at a networking event or conference. The Dashboard will also provide members with accessible news feeds from our approved experts to stay abreast of industry developments such as regulatory changes, funding calls and new services. For more information on the One Nucleus Dashboard please contact Tony@onenucleus.com
One Nucleus News
BIO2012 Massachusetts Governor Deval Patrick addresses onlookers at BIO2012
The breakfast seminar was arranged by Stockholm-Uppsala Life science and One Nucleus (London/Cambridge life science cluster) for invited media and other guests. Rob Johnson (Alacrita Consulting) acted as chairman for a panel with Joe Panetta (BIOCOM), Michael Capaldi (Edinburgh BioQuarter),Torbjörn Bjerke (Karolinska Development) and Kevin Mullin (City of South San Francisco). The audience consisted of an additional 30 experts from companies, press and cluster support groups.
The majority of One Nucleus members that attended BIO were undoubtedly focused on the 1-2-1 partnering activity with odd forays into the wider exhibition hall for more general networking, pavilion receptions or to simply touch base with their home country base at the UK Pavilion. 2012 was the first time BIO had located the 1-2-1 Business Forum in the centre of the exhibition hall. I think there was universal acceptance that this enhanced the experience for the exhibitors, being able to arrange client meetings at their own stand and hence maximise the return on their investment of attending.
Winning the award, recognising the work by the stakeholders behind the Life Science Strategy, was an excellent opportunity to ensure the UK was placed firmly in the shop window which can only be good news for our members. One Nucleus focused its proactive member engagement on two events at the start of the period in Boston, both in collaboration with our US-based MOU partners and a Scandinavian partner.
Sunday, 17 June An Executive Dinner in collaboration with MassBIO, MassMEDIC and MVA sponsored by Prior to Boston, One Nucleus had Covington & Burling LLP attracted been instrumental in ensuring Rt 50 attendees from the large Hon David Willetts MP, Minister for Pharma, biotech, medical Universities & Science, was technology and CRO base of the nominated for the 2012 BIO three regions. There was no fixed International Leadership Award agenda, more opportunity for which he was awarded during the industry leaders from three convention. Accepting the award geographical regions to learn the Minister commented „It is a real informally from each other about honour to be presented with the key trends, initiatives and market BIO International Leadership Award opportunities in the other key and to have the UK‟s work to territories present. support the life sciences industry recognised internationally. Our life Monday 18 June sciences sector is world-class, but A strong research infrastructure we are not complacent. It‟s vital we backed by leading research universities and institutes are key respond to global changes in the elements in a leading life science industry with more focus on cluster. This was one of the collaboration and more prompt messages at a breakfast seminar clinical trials. We want to ensure entitled „If we build it they will the industry continues to drive come‟. growth, foster innovation and attract overseas investment.‟
In addition to a strong research base, other assets considered by the panellists as important for attracting companies are capital, venture capital and government funding, a pool of talent and entrepreneurs, an efficient technology transfer system and a supportive local government were deemed important. Proximity to academic institutions and to international airports also being important. Favourable public policies and supportive measures such as tax benefits and infrastructure programs (roads, public transportation and utilities) are other factors that make clusters more attractive. Another theme discussed was collaboration. „ It‟s really important that clusters come together and work with each other. A few key clusters networked together supervising cross-collaboration, for instance around certain disease areas has a lot of value‟, said Chairman Robert Johnson. „I think events like this breakfast seminar are important for fostering collaboration, said Torbjörn Bjerke, Karolinska Development. We share many of the same challenges and opportunities in order to create new companies and if we can collaborate, I very much believe that we will have a stronger biopharmaceutical and biotech community in the future.‟ For more information please contact Tony@onenucleus.com
One Nucleus News
Life Science Leadership Series As many of our regular readers will know, the Life Science Leadership Series (LSLS) was our innovative strategy to replace the longer and more general Cambridge Partnering Conference in response to member
Eddy Littler, CEO Domainex
David MacIntosh (Novartis) setting out the various challenges and previous successes over Seven Ages of Manâ€™ and Professor Sir Anthony Coates who described the innovative approach of targeting dormant bacteria being undertaken at the Antibiotic Discovery Centre at St Georgeâ€&#x;s University of London. Sir Anthony finished with a call to arms to industry and academic parties to join his vision to rebuild the process of antibiotic discovery by joining his Antibiotic UK initiative. In between the opening and closing plenary sessions, there were case study presentations from emerging companies all at the early stages of drug discovery and development of new anti-infective agents. Companies including Discuva, NovaBiotics, Phico Therapeutics and Biotica highlighted their technology approach and partnering goals.
September has seen an evolution of the Healthcare Technologies theme launched in 2011. Spinning out from the initial theme was a followSince we last reported, there have on seminar hosted by TWI, been four subsequent events, focussed on building value in including the launch of out two medical technology companies. The latest thematic foci: Infectious opening plenary presentations from Diseases & Vaccines (May 2012) Paul Sherrat (TWI) and Tony Cass and Personalised Medicine (Sept (Imperial College) looked to the 2012). past and future, respectively, to set the context for the following May saw 120 delegates gather for sessions. Paul covered some of the our Infectious Diseases & Vaccines lessons learned from the past leadership event where the seven decades of commercialising programme was opened by Tim innovation whilst Tony looked to Wells of Medicines for Malaria the emerging field of biosensors in Ventures who presented the global the mobile world that will shape challenges presented by infectious how we manage and treat diseases before narrowing to focus healthcare conditions in the years on their partnerships in malaria. No to come. Following the scene -one should under-estimate the setting above, a line up of challenges, and thus by correlation experience medical technology the market opportunity, although industry executives stimulated this is likely to best be addressed debate on what the challenges for through collaborations and growth in the biosensor and IVD
market, innovation and use of smart materials and the funding and commercial opportunities represented by UK Government support, private investors and emerging Asian markets. More recently, the September 2012 LSLS event focused on Advances in Personalised Medicine. The increasing importance of biomarkers and diagnostics in diseases detection, patient management and clinical trials means the demand for technologies that can selectively and reproducibly quantify the detection of such biomarkers continues to grow. A number of commentators and industry executives are starting to suggest that in maybe as little as five years, the regulators such as FDA and EMA will require the companion diagnostic to be available before a new drug will be approved. This will mean continued integration of the appropriate
Jerry Walker, CEO Intelligent Fingerprinting
feedback. These one day events, focussed by therapeutic or technology area, attract up to 150 delegates as a maximum allowing well informed debate and effective networking.
alliances, possibly under PPIs, than by individual companies. This was complemented by the two other plenary presentations.
disciplines such as diagnostic validation, bioinformatics, medicinal chemistry and pharmacology will be required to develop new therapeutic entities. The wider context of such inter-dependent approaches has potentially far reaching implications. Continued overleaf
One Nucleus News The event opened with opened by plenary presentations from Professor Munir Pirmohamed, University of Liverpool describing how advances in pharmacogenetics will shape how patients and new medicines will be viewed as we s eek to streamline treatment strategies and pathways . This was followed by Bob Holland of Astra Zeneca presenting how his company is making personalised medicine technologies such as biomarkers, companion diagnostics and pharmacogenetics a mainstream activity in all new R&D programmes.
The opportunity for larger advisory firms, CROs and R&D organisations to engage in a targeted manner via our Partner Programme, highlighting their key value proposition and competencies through a focused exemplification in one leadership area.
Turning to each of the targeted legacy items, we are delighted to be able to demonstrate success on all three. There have been followon events in the Oncology, CNS and Healthcare Technologies themes already. Oncology has included events that have showcased Far from only focussing on the post innovative technology companies, -development use of companion open innovation and international diagnostics and biomarkers, the collaborations through events day also included a series of case hosted by Charles Russell LLP and study presentations highlighting the the Australian High Commission role of these platforms in the entire through life Sciences Queensland. R&D process, including discovery of novel therapeutic targets, The first CNS follow-on event in enhancing key decision making May 2012 saw the VP Neuroscience through surrogate end points and at Eli Lilly describe how the next product rescue by better patient year would be key to selection during clinical trials. demonstrating, or not as it turns out, the success of targeting BetaMuch like the 2012 Olympic and amyloid due to critical trials falling Paralympic Games, it was always due to report. Mike Hutton then the intention that the LSLS were went on to suggest new approaches not stand alone events, but were were moving through such the catalyst for a legacy. The evaluation such a targeting the Tau targeted form of legacy includes: protein and inflammatory pathways connected to neurodegeneration. Follow on seminars; The same event, hosted be Eversheds and sponsored by QPS, Microsites linking off the main included presenters from One Nucleus web site that will Netherlands, Singapore and Norway where the over-riding impression contain focussed archives of presentations and opinion leader left was that international collaboration was essential to articles and news relevant to that therapeutic area; deliver success in such complex
diseases areas as Alzheimer‟s diseases. Moreover, it also highlighted why companies should consider geographical regulatory environments when planning where to perform the various parts of the pre-clinical and subsequent clinical development. The development of the thematic microsites to enable these therapeutic or technology platform area sub-communities to continue the debate, sharing their thoughts and news with peers has continued within One Nucleus. The microsites will launch this [Autumn – HF to confirm] and will host the LSLS presentations, talking head videos from the advisory board members and key speakers and an archive of relevant reviews and news articles. Finally, we are pleased to announce Charles Russell LLP as the first One Nucleus Partner to join under our proposal to highlight their strengths through leadership theme examples. Of course, their service offer applies across the life science technology space and wider, however a good example of such engagement was the presentation given by Jennifer Pierce at our October 2011 oncology seminar on „Future proofing deals‟. Jennifer shared her experience of what happens when IP licensees go through M&A for example and how to take a balanced and pragmatic strategy to protecting yourself in such a dynamic business environment. For more information please contact Tony@onenucleus.com
One Nucleus News
New One Nucleus Conference – Save the date! ON Helix – 9 July 2013. Wellcome Trust Genome Campus in Hinxton Advisory Board members: Sir Bruce Ponder Cancer Research UK Ruth McKernan, CSO Neusentis / SVP Pfizer Jackie Hunter, CEO OI Pharma Partners Jon Green VP MedImmune and One Nucleus Chair Alan Palmer, CSO MS Therapeutics and One Nucleus Board member Jane Dancer, COO F-Star Harriet Fear, CEO One Nucleus Sue Dunkerton, Co-Director Healthtech & Medicines KTN Geoff Lawton, Director INMedD Dave Tapolczay, CEO MRC T Being aware of the increasing interest in translational research as pivotal for the delivery of tomorrow‟s healthcare, One Nucleus is delighted to announce the creation of a brand new event aiming at supporting organisations and businesses involved in this vital and exciting field. This one day event aims to inform delegates of how to turn early stages inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices). It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business.
Together with an outstanding Advisory Board, we are designing an exciting programme including case studies discussions, technologies presentations and practical information with as usual, plenty of space for networking.
More information will be available soon but if you or your organisation would like an early heads-up on the opportunities this event will afford, do feel free to contact Aline at Aline@onenucleus.com
One Nucleus News
New Members 365Force A4P Bioanalytical Group Almagen Ltd (BBT prog) Amadeus Capital Partners Ltd AnGes Euro Ltd APL Applied Driving Techniques Argon Design Ltd Ariel Pharma (Europe) Ltd Biotec Services International Ltd CamNutra Ltd CK Clinical Clariant College Hill Life Sciences Crawford Scientific Dehns Diasolve Ltd Dr Nicky Thelwell Edwards Ltd
Entrepreneurs Fund Management Envirotainer AB Fitnessworks Management Services GoIndustry (UK) Ltd Haemostatix Ltd Health Enterprise East Hyper Recruitment Solutions IRON Recruitment Journal of Visualized Experiments Labstract Ltd MDM Asia Mercury Pharma MVM Life Science Partners LLP NovaSecta Ltd Novus Environmental OctoPlus NV Oncology Pharma PCR Biosystems
Pharmonyze Ltd Phico Therapeutics Political Intelligence PPR Diagnostics ProPharma Partners Ltd ProsimFX Ltd QRC Consultants Ltd ReAgent Ltd Realnet Ltd Reed Scientific Specialized Print Ltd to-BBB technologies BV Transpharmation University of Reading Academic Legal Services Vectura Plc Vertex Pharmaceuticals WIL Research
One Nucleus Events to Spring 2013 Date
Charles Russell, London
Stevenage Bioscience Catalyst
QEII Centre, Westminster, London
London Pub Social
Life Science Leadership Series: Antibodies and Protein Based Therapeutics
Babraham Research Campus
One Nucleus Sponsors Corporate Patron